Myovant Sciences Ltd. Announces Pricing of Initial Public Offering
27 Oct 2016 at 12:00 pm ETPDF Version
HAMILTON, Bermuda, Oct. 27, 2016 /PRNewswire/ — Myovant Sciences Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 14,500,000 common shares at a price of $15.00 per share. The common shares of Myovant Sciences Ltd. have been approved for listing on the New York Stock Exchange and are expected to begin trading under the ticker symbol “MYOV” on October 27, 2016. All of the common shares are being offered by Myovant Sciences Ltd. In addition, Myovant Sciences Ltd. has granted the underwriters a 30-day option to purchase up to 2,175,000 additional common shares.
Citigroup Global Markets Inc., Cowen and Company, LLC, Evercore Group L.L.C. and Barclays Capital Inc. are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager and Robert W. Baird & Co. Incorporated is acting as co-manager for the offering.
The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: (800) 831-9146 (toll free), e-mail: firstname.lastname@example.org; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, telephone: (631) 274-2806; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, telephone: (212) 653-9054, e-mail: email@example.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, e-mail: Barclaysprospectus@broadridge.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on October 26, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. Myovant’s lead product candidate is relugolix, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist. Myovant plans to initiate three multinational Phase 3 clinical programs for relugolix, one in women with heavy menstrual bleeding associated with uterine fibroids, a second in women with endometriosis-associated pain, and a third in men with advanced prostate cancer.
Logo – http://photos.prnewswire.com/prnh/20161011/427661LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/myovant-sciences-ltd-announces-pricing-of-initial-public-offering-300352316.html
SOURCE Myovant Sciences Ltd.